[go: up one dir, main page]

GB202407700D0 - F-actin binding agents - Google Patents

F-actin binding agents

Info

Publication number
GB202407700D0
GB202407700D0 GBGB2407700.0A GB202407700A GB202407700D0 GB 202407700 D0 GB202407700 D0 GB 202407700D0 GB 202407700 A GB202407700 A GB 202407700A GB 202407700 D0 GB202407700 D0 GB 202407700D0
Authority
GB
United Kingdom
Prior art keywords
binding agents
actin binding
actin
agents
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2407700.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Francis Crick Institute Ltd
Original Assignee
Francis Crick Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francis Crick Institute Ltd filed Critical Francis Crick Institute Ltd
Priority to GBGB2407700.0A priority Critical patent/GB202407700D0/en
Publication of GB202407700D0 publication Critical patent/GB202407700D0/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
GBGB2407700.0A 2024-05-30 2024-05-30 F-actin binding agents Pending GB202407700D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2407700.0A GB202407700D0 (en) 2024-05-30 2024-05-30 F-actin binding agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2407700.0A GB202407700D0 (en) 2024-05-30 2024-05-30 F-actin binding agents

Publications (1)

Publication Number Publication Date
GB202407700D0 true GB202407700D0 (en) 2024-07-17

Family

ID=91620860

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2407700.0A Pending GB202407700D0 (en) 2024-05-30 2024-05-30 F-actin binding agents

Country Status (1)

Country Link
GB (1) GB202407700D0 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US7723485B2 (en) 2007-05-08 2010-05-25 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
WO2023203198A1 (en) 2022-04-21 2023-10-26 The Francis Crick Institute Limited Bispecific binding agent
WO2024018062A1 (en) 2022-07-21 2024-01-25 The Francis Crick Institute Limited Immunoconjugate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US7723485B2 (en) 2007-05-08 2010-05-25 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2023203198A1 (en) 2022-04-21 2023-10-26 The Francis Crick Institute Limited Bispecific binding agent
WO2024018062A1 (en) 2022-07-21 2024-01-25 The Francis Crick Institute Limited Immunoconjugate

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
"Phage antibodies: filamentous phage displaying antibody variable domains", NATURE, vol. 348, no. 6301, pages 552 - 554
"Remington's Pharmaceutical Sciences", 2000, LIPPINCOTT, WILLIAMS & WILKINS
ALTSCHUL ET AL., METHODS IN ENZYMOLOGY, vol. 266, 1996, pages 460 - 480
ASHMAN, N. ET AL.: "Non-internalising antibody-drug conjugates", CHEM SOC REV, vol. 51, 2022, pages 9182
BARGH, J.D. ET AL.: "Cleavable linkers in antibody-drug conjugates", CHEM. SOC. REV., vol. 48, 2019, pages 4361 - 4374, XP009517547, DOI: 10.1039/c8cs00676h
BECK, NAT REV DRUG DISCOV, vol. 16, no. 5, 2017, pages 315 - 337
CASTRO-DOPICO, T. & CLATWORTHY, M.: "IgG and Fcy Receptors in Intestinal Immunity and Inflammation.", FRONTIERS IN IMMUNOLOGY, vol. 10, 2019, pages 805
CHALOUNIDOLL, J EXP CLIN CANCER RES., vol. 37, no. 1, 2018, pages 20
CHOMET, M. ET AL.: "State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET", BIOCONJUGATE CHEMISTRY, vol. 32, 2021, pages 1315 - 1330
DIMASI ET AL., MOL PHARMACEUTICALS, vol. 14, no. 5, 2017, pages 1501 - 1516
DOMINGUEZ, R.HOLMES, K. C.: "Actin Structure and Function", ANNU REV BIOPHYS, vol. 40, 2011, pages 169 - 186
DORNAN ET AL., BLOOD, vol. 114, no. 13, 2009, pages 2721 - 2729
ECKERMAN, K. F.ENZO, A.: "MIRD: Radionuclide Data and Decay Schemes", 2008, SOCIETY OF NUCLEAR MEDICINE
GÉBLEUXCASI, PHARMACOL THER, vol. 167, 2016, pages 48 - 59
GIAMPAZOLIAS, E. ET AL.: "Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity", CELL, vol. 184, no. 15, 2021, pages 4016 - 4031, XP086701206, DOI: 10.1016/j.cell.2021.05.021
HAMBLETT ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 7063 - 7070
HAND, P. ET AL.: "Structure of the complex of F-actin and DNGR-1, a C-type lectin receptor involved in dendritic cell crosspresentation of dead cell-associated antigens", IMMUNITY, vol. 42, no. 5, 2015, pages 839 - 849
HELEN E. CHADDSTEVEN M. CHAMOW: "Therapeutic antibody expression technology", CURRENT OPINION IN BIOTECHNOLOGY, vol. 12, no. 2, 1 April 2001 (2001-04-01), pages 188 - 194, XP001183758, DOI: 10.1016/S0958-1669(00)00198-1
HOLIK, H. A. ET AL.: "The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker", MOLECULES, vol. 27, 2022, pages 3062
HUANGMILLER, ADV. APPL. MATH., vol. 12, 1991, pages 337 - 357
HUSTON ET AL., PROC. NATL. ACAD. SD. USA, vol. 85, 1988, pages 5879
IVANOVA, J. R. ET AL.: "Designed Ankyrin Repeat Proteins as Actin Labels of Distinct Cytoskeletal Structures in Living Cells", ACS NANO, vol. 18, 2024, pages 8919 - 8933
J G R HURRELL: "Monoclonal Hybridoma Antibodies: Techniques and Applications", 1982, CRC PRESS
JUNUTULA ET AL., NATURE BIOTECH., vol. 26, no. 8, 2008, pages 925 - 932
KHONGORZUL, P. ET AL.: "Antibody-Drug Conjugates: A Comprehensive Review", MOL CANCER RES, vol. 18, no. 1, 2020, pages 3 - 19, XP055723911, DOI: 10.1158/1541-7786.MCR-19-0582
KOHLER, G.MILSTEIN, C.: "Continuous cultures of fused cells secreting antibody of predefined specificity", NATURE, vol. 256, no. 5517, 1975, pages 495, XP037052082, DOI: 10.1038/256495a0
LOPATA, A. ET AL.: "Affimer proteins for F-actin: novel affinity reagents that label F-actin in live and fixed cells", SCIENTIFIC REPORTS, vol. 8, 2018, pages 6572
MCCAFFERTY, J.GRIFFITHS, A.WINTER, G.CHISWELL, D.: "Phage antibodies: filamentous phage displaying antibody variable domains", NATURE, vol. 348, no. 6301, 1990, pages 552 - 554
MORRISON ET AL., PROC. NATL. ACAD. SD. USA, vol. 81, 1984, pages 6851 - 6855
NEUBERGER ET AL., 8TH INTERNATIONAL BIOTECHNOLOGY SYMPOSIUM, vol. 2, 1988, pages 792 - 799
PIKTEL, E. ET AL.: "Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target.", INT. J. MOL. SCI., vol. 19, 2018, pages 2516
SAMBROOK, J.RUSSEL, D.W.: "Molecular Cloning, A Laboratory Manual.", 2001, COLD SPRING HARBOR LABORATORY PRESS
SANDERSON ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 843 - 852
SCHMITZ UVERSMOLD AKAUFMANN PFRANK HG: "Phage display: a molecular tool for the generation of antibodies--a review", PLACENTA, vol. 21, 2000, pages 106 - 12
SGOUROS, G. ET AL.: "Radiopharmaceutical therapy in cancer: clinical advantages and challenges", NATURE REVIEWS DRUG DISCOVERY, vol. 19, 2020, pages 589 - 608
SIEGEL DL, RECOMBINANT MONOCLONAL ANTIBODY TECHNOLOGY, 2000
SIEGEL DL, RECOMBINANT MONOCLONAL ANTIBODY TECHNOLOGY, 2002
SKERRA ET AL., SCIENCE, vol. 242, 1988, pages 1038
STAUDACHER, A. H. ET AL.: "Therapeutic targeting of tumor hypoxia and necrosis with antibody a-radioconjugates", ANTIBODY THERAPEUTICS, vol. 1, no. 2, 2018, pages 55 - 63
WARD ET AL., NATURE, vol. 341, 1989, pages 544
WINTERMILSTEIN, NATURE, vol. 349, 1991, pages 293 - 299

Similar Documents

Publication Publication Date Title
IL316140A (en) Nectin-4 binding agents
GB202407700D0 (en) F-actin binding agents
GB202214979D0 (en) Binding protein
GB202302043D0 (en) Binding proteins
CA232701S (en) Tele-plier
CA232700S (en) Tele-plier
CA232699S (en) Tele-plier
CA231635S (en) Cardprotector
CA230174S (en) Kettlebell
GB202501309D0 (en) Binding domain
GB202401207D0 (en) Binding domain
GB202508634D0 (en) Combinations
GB202503115D0 (en) Combinations
GB202408320D0 (en) Combinations
GB202408217D0 (en) Combinations
GB202416230D0 (en) Part
GB202404664D0 (en) cover
GB202401380D0 (en) Immunoassays
GB202508283D0 (en) Combination
GB202508291D0 (en) Combination
GB202508274D0 (en) Combination
GB202508265D0 (en) Combination
GB202508289D0 (en) Combination
GB202508288D0 (en) Combination
GB202508255D0 (en) Combination